lisofylline

Small moleculeexperimental

Lisofylline (LSF) is a synthetic small molecule with novel anti-inflammatory properties. LSF can effectively prevent type 1 diabetes in preclinical models and improves the function and viability of isolated or transplanted pancreatic islets. It is a metabolite of pentoxifylline. — Wikipedia

Clinical trial activity

4 trials · 24 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 1, 1994 (NCT00000579)

Timeline

1990s

Jan 1, 1994
Earliest Phase 3 Sponsor(trial)

2000s

Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Jan 1, 2009
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Unspecified targetUnclear
Unclear

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O

Mol. weight: 280.33 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaLisofylline ↗
ChEMBLCHEMBL1411 ↗

Also known as

1-(5'-hydroxyhexyl)-3,7-dimethylxanthine
1-(5r-hydroxyhexyl)-3,7-dimethylxanthine
1h-purine-2,6-dione, 3,7-dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl-
3,7-dimethyl-1-(5-hydroxyhexyl)xanthine
a-802710
bl 194
ct-1501r
ct-1501r
ct-1501r
lisofylline
lisofylline
lisofylline
lisofylline
lisofylline
lysofylline
lysofylline
protec
protec

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01603121	Phase 1/Phase 2 (Phase 2)	Feb 1, 2012	Eastern Virginia Medical School
NCT00896077	Phase 1/Phase 2 (Phase 2)	May 1, 2009	DiaKine Therapeutics, Inc.
NCT00464555	Phase 2	Dec 1, 2006	National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Miami
NCT00000579	Phase 3	Sep 1, 1994	Baylor University, Duke University, Harvard University, Johns Hopkins University, Latter Day Saints Hospital, Louisiana State University, Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI), The University of Texas, Dallas, University of British Columbia, University of California, San Francisco, University of Chicago, University of Colorado, Denver, University of Massachusetts, University of Pittsburgh, University of Rochester, University of Virginia, Vanderbilt University, Wake Forest University

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (24)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Baylor University	Academic/Hospital	1	0	1	1994
DiaKine Therapeutics, Inc.	For profit	1	1	1	2009
Duke University	Academic/Hospital	1	0	1	1994
Eastern Virginia Medical School	Academic/Hospital	1	1	1	2012
Harvard University	Academic/Hospital	1	0	1	1994
Johns Hopkins University	Academic/Hospital	1	0	1	1994
Latter Day Saints Hospital	Academic/Hospital	1	0	1	1994
Louisiana State University	Academic/Hospital	1	0	1	1994
Mayo Clinic	Academic/Hospital	1	0	1	1994
National Heart, Lung, and Blood Institute (NHLBI)	Government	1	1	1	1994
National Institute of Allergy and Infectious Diseases (NIAID)	Government	1	1	1	2006
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Government	1	0	1	2006
The University of Texas, Dallas	Academic/Hospital	1	0	1	1994
University of British Columbia	Academic/Hospital	1	0	1	1994
University of California, San Francisco	Academic/Hospital	1	0	1	1994
University of Chicago	Academic/Hospital	1	0	1	1994
University of Colorado, Denver	Academic/Hospital	1	0	1	1994
University of Massachusetts	Academic/Hospital	1	0	1	1994
University of Miami	Academic/Hospital	1	0	1	2006
University of Pittsburgh	Academic/Hospital	1	0	1	1994

24 organizations

Page 1 / 2